cgp 52411 has been researched along with Bladder Cancer in 2 studies
4,5-dianilinophthalimide: structure given in first source
4,5-dianilinophthalimide : Phthalimide substituted at the 4- and 5-positions by anilino groups.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dinney, CP | 1 |
| Parker, C | 1 |
| Dong, Z | 1 |
| Fan, D | 1 |
| Eve, BY | 1 |
| Bucana, C | 1 |
| Radinsky, R | 1 |
| Buchdunger, E | 1 |
| Mett, H | 1 |
| Trinks, U | 1 |
| Regenass, U | 1 |
| Müller, M | 1 |
| Meyer, T | 1 |
| Beilstein, P | 1 |
| Wirz, B | 1 |
| Schneider, P | 1 |
| Traxler, P | 1 |
2 other studies available for cgp 52411 and Bladder Cancer
| Article | Year |
|---|---|
Therapy of human transitional cell carcinoma of the bladder by oral administration of the epidermal growth factor receptor protein tyrosine kinase inhibitor 4,5-dianilinophthalimide.
Topics: Adenosine Triphosphate; Administration, Oral; Animals; Carcinoma, Transitional Cell; Cell Division; | 1997 |
4,5-bis(4-fluoroanilino)phthalimide: A selective inhibitor of the epidermal growth factor receptor signal transduction pathway with potent in vivo antitumor activity.
Topics: 3T3 Cells; Animals; Antineoplastic Agents; Biotransformation; Carcinoma, Squamous Cell; Cell Line, T | 1995 |